JP2018519847A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519847A5 JP2018519847A5 JP2018510008A JP2018510008A JP2018519847A5 JP 2018519847 A5 JP2018519847 A5 JP 2018519847A5 JP 2018510008 A JP2018510008 A JP 2018510008A JP 2018510008 A JP2018510008 A JP 2018510008A JP 2018519847 A5 JP2018519847 A5 JP 2018519847A5
- Authority
- JP
- Japan
- Prior art keywords
- epitope
- mutation
- adenovirus
- oncolytic adenovirus
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562156748P | 2015-05-04 | 2015-05-04 | |
| US62/156,748 | 2015-05-04 | ||
| PCT/IB2016/052554 WO2016178167A1 (en) | 2015-05-04 | 2016-05-04 | Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519847A JP2018519847A (ja) | 2018-07-26 |
| JP2018519847A5 true JP2018519847A5 (https=) | 2019-06-13 |
| JP6740340B2 JP6740340B2 (ja) | 2020-08-12 |
Family
ID=55967340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018510008A Active JP6740340B2 (ja) | 2015-05-04 | 2016-05-04 | 免疫優性アデノウイルスエピトープに突然変異を有する腫瘍溶解性アデノウイルスおよび癌処置におけるそれらの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11000560B2 (https=) |
| EP (1) | EP3292142B1 (https=) |
| JP (1) | JP6740340B2 (https=) |
| CN (1) | CN107849111B (https=) |
| AU (1) | AU2016257196B2 (https=) |
| ES (1) | ES2987442T3 (https=) |
| WO (1) | WO2016178167A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2352756T3 (da) * | 2008-11-24 | 2012-12-03 | Helmholtz Zentrum Muenchen | Højaffin T-cellereceptor og anvendelse af denne |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| WO2017155935A1 (en) | 2016-03-07 | 2017-09-14 | The Johns Hopkins University | Pharmaceutical agents targeting cancer stem cells |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| WO2018075830A1 (en) | 2016-10-19 | 2018-04-26 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
| WO2019032866A1 (en) * | 2017-08-09 | 2019-02-14 | Ohio State Innovation Foundation | ONCOLYTIC VIRUS CARRYING E-CADHERIN AND USES THEREOF |
| CN109576231B (zh) | 2017-09-28 | 2022-03-25 | 北京康万达医药科技有限公司 | 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
| KR102439221B1 (ko) | 2017-12-14 | 2022-09-01 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| KR20210031852A (ko) * | 2018-03-05 | 2021-03-23 | 클리니쿰 레히츠 데어 이자르 데어 테크니쉔 우니베르지테트 뮌헨 | 종양 세포 붕괴성 아데노바이러스와 cdk4/6 억제제의 조합물에 의한 종양의 치료 |
| GB201804468D0 (en) | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | PeptiCRAd Cancer Therapy |
| EP3773649A4 (en) | 2018-03-28 | 2022-02-23 | EpicentRx, Inc. | PERSONALIZED CANCER VACCINE |
| CN110856751B (zh) | 2018-08-24 | 2024-12-03 | 杭州康万达医药科技有限公司 | 包含核酸及tcr修饰的免疫细胞的治疗剂及其应用 |
| CN110669740B (zh) * | 2019-07-16 | 2021-10-08 | 伍泽堂 | 溶瘤病毒及其应用和治疗癌症的药物 |
| KR20220079551A (ko) * | 2019-09-05 | 2022-06-13 | 클리니쿰 레히츠 데어 이자르 데어 테크니쉔 우니베르지테트 뮌헨 | 종양 세포 붕괴성 아데노바이러스, cdk4/6 억제제 및 추가의 치료 활성제의 조합물에 의한 종양의 치료 |
| CN114292830B (zh) * | 2021-12-31 | 2024-05-03 | 复旦大学 | 蛋白SaCas9的抗原表位及其在基因编辑中的应用 |
| WO2024196669A2 (en) * | 2023-03-17 | 2024-09-26 | Walking Fish Therapeutics, Inc. | Methods for in vivo editing of b cells |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
| US5922315A (en) * | 1997-01-24 | 1999-07-13 | Genetic Therapy, Inc. | Adenoviruses having altered hexon proteins |
| US7749492B2 (en) | 2001-01-05 | 2010-07-06 | Nationwide Children's Hospital, Inc. | AAV vectors and methods |
| US20060147420A1 (en) | 2004-03-10 | 2006-07-06 | Juan Fueyo | Oncolytic adenovirus armed with therapeutic genes |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| DE602005017743D1 (de) * | 2004-01-23 | 2009-12-31 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| US20080187954A1 (en) | 2004-03-10 | 2008-08-07 | Lonza Ltd. | Method For Producing Antibodies |
| US20080292592A1 (en) | 2004-04-30 | 2008-11-27 | Sunil Chada | Oncolytic Adenovirus Armed with Therapeutic Genes |
| JP4976294B2 (ja) * | 2005-08-03 | 2012-07-18 | 株式会社医学生物学研究所 | 細胞傷害性ｔ細胞エピトープペプチド及びその用途 |
| WO2009117656A2 (en) * | 2008-03-21 | 2009-09-24 | Vectorlogics,Inc. | Capsid-incorporated antigen for novel adenovirus vaccine |
| AU2009332883B2 (en) | 2008-12-22 | 2015-05-21 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| ES2385251B1 (es) * | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| EP2448599A1 (en) * | 2009-06-30 | 2012-05-09 | Philogen S.p.A. | Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer |
| US20130029358A1 (en) * | 2010-04-01 | 2013-01-31 | Ludwig Institute For Cancer Research Ltd. | Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof |
| CN103237889B (zh) * | 2010-08-16 | 2017-04-05 | 萨克生物研究学院 | 腺病毒组装方法 |
| US20130323205A1 (en) | 2010-09-24 | 2013-12-05 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| CA2819182C (en) * | 2010-11-25 | 2021-06-29 | Imnate Sarl | Modulation of antigen immunogenicity by deleting epitopes recognized by nkt cells |
| WO2013116778A2 (en) * | 2012-02-02 | 2013-08-08 | Board Of Regents | Immunogenic adenovirus |
| US9017672B2 (en) * | 2012-05-11 | 2015-04-28 | Immunicum Aktiebolag | Hexon Tat-PTD modified adenovirus and uses thereof |
-
2016
- 2016-05-04 ES ES16722384T patent/ES2987442T3/es active Active
- 2016-05-04 AU AU2016257196A patent/AU2016257196B2/en active Active
- 2016-05-04 JP JP2018510008A patent/JP6740340B2/ja active Active
- 2016-05-04 CN CN201680031591.6A patent/CN107849111B/zh active Active
- 2016-05-04 WO PCT/IB2016/052554 patent/WO2016178167A1/en not_active Ceased
- 2016-05-04 US US15/571,698 patent/US11000560B2/en active Active
- 2016-05-04 EP EP16722384.1A patent/EP3292142B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519847A5 (https=) | ||
| JP6325459B2 (ja) | 腫瘍関連異種抗原を発現するアデノウイルス | |
| JP6740340B2 (ja) | 免疫優性アデノウイルスエピトープに突然変異を有する腫瘍溶解性アデノウイルスおよび癌処置におけるそれらの使用 | |
| Anderson et al. | Plasmid DNA and viral vector-based vaccines for the treatment of cancer | |
| JP6945301B2 (ja) | Ｈｐｖおよび関連する疾病のための免疫増強治療ワクチン | |
| JP7098330B2 (ja) | Ｈｐｖワクチン | |
| JP2015506704A5 (https=) | ||
| JP6566214B2 (ja) | Ｒｅｉｃ遺伝子を発現する制限増殖型アデノウイルス | |
| JP5690814B2 (ja) | 抗原特異的な免疫応答を高めるための組成物及び方法 | |
| RU2016146664A (ru) | Аденовирус, содержащий альбумин-связывающий участок | |
| US10435672B2 (en) | Genetically stable oncolytic RNA virus, method of manufacturing and use thereof | |
| Riezebos-Brilman et al. | A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer | |
| WO2006125381A1 (en) | Tumor targeting gene-virus zd55-il-24, construction method and application thereof | |
| JP7816735B2 (ja) | 腫瘍溶解性ウイルス及びそれを用いたがん治療 | |
| CN101880688B (zh) | 一种使复制缺陷型腺病毒选择性复制的方法和用途 | |
| WO2026041811A1 (en) | Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell | |
| CN121344098A (zh) | Gbm靶向性溶瘤腺病毒载体及其构建方法和应用 | |
| Guinn et al. | International society for cell and gene therapy of cancer (ISCGT) annual meeting: conference overview and introduction to the symposium papers | |
| Ji et al. | Oncolytic viruses in lung cancer: mechanisms of action and research progress | |
| HK40012146A (zh) | 表达异源肿瘤相关抗原的腺病毒 | |
| HK1205182B (en) | Adenoviruses expressing heterologous tumor-associated antigens | |
| Kim | Oncolytic vaccinia virus expressing 4-1BBL inhibits tumor growth by increasing CD8+ T cells in B16F10 tumor model | |
| Kirn et al. | 635. Systemic Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF | |
| Aggen et al. | 356. CD8: Class I MHC Interactions In. fluence T Cell Activity Mediated by Chimeric Antigen Receptors | |
| Artlip et al. | 139. Manufacture of a Replication-Selective and Enhanced-Lytic Adenovirus Vector |